ProFem develops new medicines for gynaecological diseases addressing hitherto unmet medical needs and therefore high market potential. The focus of interest has developed around chronic urogenital infections, mostly associated with biofilm growth, which up to now represents an unsolved medical problem in some extremely relevant indications. The highly innovative approach is based on the therapeutic interference with microbial adhesion molecules and biofilm disruption.
R&D:Profem´s 1st product is a new and patented combination medicine providing fast and effective topical treatment of recurrent vulvovaginal candidiasis by specifically disrupting the biofilm causing the disease. The project is in the phase of clinical development, the clinical study program is planned to be completed in 2018. Pipeline projects are directed against chronic or recurrent bacterial urogenital infections.
Riglergasse 4
1180 Vienna
Vienna
Contact: Marion Noe-Letsching (PhD, MD, CEO)
Telephone: +43 (676) 72030-70
Email: marion.noe@profem.at
Website